Abstract: OBJECTIVE To study the bone metabolism in corticosteroids-treated patients with risedronate treatment. METHODS Forty ambulatory patients who took high-dose corticosteroids therapy, were randomly, double-blindly divided into two groups: treatment group (20 patients) were treated with risedronate sodium(5 mg·d^-1) and control group(20 patients) were treated with placebo for 12 months. The efficacy of the treatment was evaluated by bone mineral density(BMD) measurements at spine and hip at the 12th month of the treatment and by the measurement of bone turnover marks. RESULTS After 12 months, in treatment group, BMD in the lumbar vertebrae and hip was significantly increased, and bone turnover marks ameliorated significantly compared with control group. CONCLUSION The risedoronate can increase BMD and ameliorate bone metabolism in patients with corticosteroids-induced osteoporosis.